中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
14期
2146-2148
,共3页
癌,非小细胞肺%肿瘤标志物%角蛋白质类
癌,非小細胞肺%腫瘤標誌物%角蛋白質類
암,비소세포폐%종류표지물%각단백질류
Carcinoma,non-small-cell lung%Tumor marker%Keratins
目的：探讨血清细胞角蛋白19片段（ CYFRA21-1）水平变化应用于晚期非小细胞肺癌（NSCLC）患者化疗疗效评价的意义。方法用ELISA法分析86例晚期NSCLC患者血清中经一线化疗药物（吉西他滨＋顺铂）化疗前后血清中CYFRA21-1水平，同时与42例健康对照人群血清CYFRA21-1水平作对比分析。结果与健康对照组CYFRA21-1（1．98±1．17）μg/L相比，晚期NSCLC患者血清中CYFRA21-1水平[（17．36±13．28）μg/L]明显升高（t＝12．56，P＜0．05），且肺鳞癌患者血清中CYFRA21-1为（25．47±15.31）μg/L，明显高于肺腺癌患者的（17．36±13．28）μg/L（t＝5．84，P＜0．05）。此外，对一线化疗药物有效的患者，化疗后血清中CYFRA21-1水平明显低于化疗前，而对一线化疗药物无效或有抵抗的患者血清中CYFRA21-1水平在化疗前后变化并不明显，甚至有升高的趋势。结论血清CYFRA21-1可作为晚期NSCLC患者化疗疗效早期的有效评价指标。
目的：探討血清細胞角蛋白19片段（ CYFRA21-1）水平變化應用于晚期非小細胞肺癌（NSCLC）患者化療療效評價的意義。方法用ELISA法分析86例晚期NSCLC患者血清中經一線化療藥物（吉西他濱＋順鉑）化療前後血清中CYFRA21-1水平，同時與42例健康對照人群血清CYFRA21-1水平作對比分析。結果與健康對照組CYFRA21-1（1．98±1．17）μg/L相比，晚期NSCLC患者血清中CYFRA21-1水平[（17．36±13．28）μg/L]明顯升高（t＝12．56，P＜0．05），且肺鱗癌患者血清中CYFRA21-1為（25．47±15.31）μg/L，明顯高于肺腺癌患者的（17．36±13．28）μg/L（t＝5．84，P＜0．05）。此外，對一線化療藥物有效的患者，化療後血清中CYFRA21-1水平明顯低于化療前，而對一線化療藥物無效或有牴抗的患者血清中CYFRA21-1水平在化療前後變化併不明顯，甚至有升高的趨勢。結論血清CYFRA21-1可作為晚期NSCLC患者化療療效早期的有效評價指標。
목적：탐토혈청세포각단백19편단（ CYFRA21-1）수평변화응용우만기비소세포폐암（NSCLC）환자화료료효평개적의의。방법용ELISA법분석86례만기NSCLC환자혈청중경일선화료약물（길서타빈＋순박）화료전후혈청중CYFRA21-1수평，동시여42례건강대조인군혈청CYFRA21-1수평작대비분석。결과여건강대조조CYFRA21-1（1．98±1．17）μg/L상비，만기NSCLC환자혈청중CYFRA21-1수평[（17．36±13．28）μg/L]명현승고（t＝12．56，P＜0．05），차폐린암환자혈청중CYFRA21-1위（25．47±15.31）μg/L，명현고우폐선암환자적（17．36±13．28）μg/L（t＝5．84，P＜0．05）。차외，대일선화료약물유효적환자，화료후혈청중CYFRA21-1수평명현저우화료전，이대일선화료약물무효혹유저항적환자혈청중CYFRA21-1수평재화료전후변화병불명현，심지유승고적추세。결론혈청CYFRA21-1가작위만기NSCLC환자화료료효조기적유효평개지표。
Objective To investigate the siginicance of evaluation of chemotherapy the changes of serum concentration of CYFRA21-1 application in patients with advanced non-small cell lung cancer (NSCLC).Methods Enzyme linked immunosorbent assay ( ELISA) was used to analyze of 86 cases of advanced NSCLC in the serum of the patients after first-line chemotherapy(gemcitabine +cisplatin) difference between the changes of CYFRA21-1 con-centration in serum before and after chemotherapy ,and 42 cases of normal healthy control CYFRA 21-1 concentration in human serum were analyzed .Results Compared with healthy controls ,serum concentrations of CYFRA 21-1 in pa-tients with advanced NSCLC increased significantly [(1.98 ±1.17)μg/L vs (17.36 ±13.28)μg/L,t=12.56,P<0.05],and the concentration of CYFRA21-1 in serum of patients with lung squamous cell carcinoma was significantly higher than that in patients with lung adenocarcinoma [(25.47 ±15.31)μg/L vs (17.36 ±13.28)μg/L, t=5.84, P<0.05] .In addition to first-line chemotherapy in patients with NSCLC patients ,the serum concentration of CY-FRA21-1 significantly lower than before chemotherapy and after chemotherapy ,the first-line chemotherapy drug was invalid or CYFRA21-1 concentration in serum of patients with chemotherapy resistance in before and after the change is not obvious ,even there was a trend of rising .Conclusion Serum CYFRA21-1 can be used as the curative effect of chemotherapy in patients with advanced NSCLC effective evaluation index of early .
